calf serum
Animal productexperimental
Actovegin is a highly filtered extract obtained from calf blood which enhances aerobic oxidation in mammals. This improves absorption of glucose and oxygen uptake in tissue, which may enhance physical performance and stamina. Local utilisation is allowed in countries like Canada and Sweden. Doctors like Hans-Wilhelm Müller-Wohlfahrt and Richard Steadman think Actovegin should be allowed in general. Others think there is not enough research, and persons from the World Anti-Doping Agency like Olivier Rabin is sceptical that it is having more than a placebo effect. — Wikipedia
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00483730)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaActovegin ↗
- ChEMBLCHEMBL2108885 ↗
Also known as
- actovegin
- actovegin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03469349 | Phase 3 | May 1, 2018 | Takeda |
| NCT03543917 | Phase 1 | Aug 8, 2017 | Fundatia Bio-Forum |
| NCT03260153 | N/A | Jan 31, 2017 | Beijing Stroke Association, Capital Medical University |
| NCT01582854 | Phase 3 | Jun 1, 2012 | Takeda |
| NCT00483730 | Phase 3 | Dec 1, 2006 | Nycomed |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2012 |
| Beijing Stroke Association | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Fundatia Bio-Forum | For profit | 1 | 1 | 1 | 2017 |
| Nycomed | For profit | 1 | 1 | 1 | 2006 |
5 organizations
Page 1 / 1